KOBV Portal

Hits per page

hits 1 - 10 | 534 hits

Sorting

Online Resource

Features and Outcomes of Histologically Proven Myocarditis With Fulminant Presentation

Kanaoka, Koshiro ; Onoue, Kenji ; Terasaki, Satoshi ; [et al.]

Ovid Technologies (Wolters Kluwer Health) ; 2022

In: Circulation Vol. 146, No. 19 ( 2022-11-08), p. 1425-1433

add to watchlist on the watchlist

Details

In: Circulation, Ovid Technologies (Wolters Kluwer Health), Vol. 146, No. 19 ( 2022-11-08), p. 1425-1433

Abstract: Fulminant myocarditis presentation (FMP) is a rare and severe presentation of myocarditis. The natural history of FMP and its clinical features associated with poor outcomes are incompletely understood because there is a lack of generalizable evidence. Methods: This multicenter retrospective cohort study included patients hospitalized with histologically proven myocarditis who underwent catecholamine or mechanical support from 235 cardiovascular training hospitals across Japan between April 2012 and March 2017. Clinical features and the prognostic predictors of death or heart transplantation within 90 days on the basis of clinical and pathologic findings were determined using the Kaplan-Meier method, log-rank test, and Cox regression analysis. Results: This study included 344 patients with histologically proven FMP (median age, 54 years; 40% female). The median follow-up was 600 days (interquartile range, 36 to 1599 days) and the cumulative risk of death or heart transplantation at 90 days was 29% (n=98). Results from multivariable Cox regression analysis showed that older age, nonsinus rhythm, low left ventricular wall motion ( 〈 40%) on admission, and ventricular tachycardia or fibrillation on admission day were associated with worse 90-day survival. Severe histologic damage (damaged cardiomyocytes comprising ≥50% of the total cardiomyocytes) was associated with a worse 90-day prognosis in patients with lymphocytic myocarditis. Conclusions: The results from analyses of data from this multicenter registry demonstrated that patients with FMP are at a higher risk of death or heart transplantation in real-world settings. These observations inform which clinical and pathologic findings may be useful for prognostication in FMP. Registration: URL: https://www.umin.ac.jp/ctr ; Unique identifier: UMIN000039763.

Type of Medium: Online Resource

ISSN: 0009-7322 , 1524-4539

URL: Article

DOI: 10.1161/CIRCULATIONAHA.121.058869

Language: English

Publisher: Ovid Technologies (Wolters Kluwer Health)

Publication Date: 2022

detail.hit.zdb_id: 1466401-X

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis

Chuma, Makoto ; Uojima, Haruki ; Hiraoka, Atsushi ; [et al.]

Wiley ; 2021

In: Hepatology Research Vol. 51, No. 2 ( 2021-02), p. 201-215

add to watchlist on the watchlist

Details

In: Hepatology Research, Wiley, Vol. 51, No. 2 ( 2021-02), p. 201-215

Abstract: To assess the safety, efficacy, and prognostic impact of clinical factors associated with lenvatinib treatment in highly advanced hepatocellular carcinoma (HCC) with tumor thrombus in the main portal vein trunk (VP4) or tumor with more than 50% liver occupation (tm50%LO). Methods A total of 61 highly advanced HCC patients (41 patients with tm50%LO and 20 patients with VP4) who were treated with lenvatinib at multicenter were enrolled and retrospectively analyzed for treatment outcomes according to their clinical status, including tumor morphology. Results The most frequent grade ≥3 adverse event in tm50%LO HCC was elevated aspartate aminotransferase (17.1%). Objective response rates were 37.5% and 0% in tm50%LO HCC patients with Child–Pugh grade (CP)‐A and CP‐B, respectively, and 26.7% and 0% in VP4 HCC patients with CP‐A and CP‐B, respectively. Estimated median progression‐free survival and overall survival were 132 days and 229 days, and 101 days and 201 days in patients with tm50%LO and VP4, respectively. In multivariate analysis, modified albumin‐bilirubin grade (hazard ratio 0.372, 95% CI 0.157–0.887; p = 0.0241) and tumor morphology (hazard ratio 0.322, 95% CI 0.116–0.889; p = 0.0287) were independently associated with progression‐free survival in patients with tm50%LO HCC. In VP4 HCC, median progression‐free survival was worse in CP‐B (57 days) than in CP‐A patients (137 days, p = 0.0462). Conclusions Lenvatinib treatment offers a benefit in highly advanced HCC (tm50%LO or VP4) patients with good liver function or nodular‐type tumor. The various characteristics identified in this study might be useful as indicators of lenvatinib treatment in highly advanced HCC with tm50%LO or VP4, which are considered very refractory cancers.

Type of Medium: Online Resource

ISSN: 1386-6346 , 1872-034X

URL: Issue

URL: Article

DOI: 10.1111/hepr.v51.2

DOI: 10.1111/hepr.13592

Language: English

Publisher: Wiley

Publication Date: 2021

detail.hit.zdb_id: 2006439-1

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Cardiovascular Prognosis in Drug-Resistant Hypertension Stratified by 24-Hour Ambulatory Blood Pressure: The JAMP Study

Kario, Kazuomi ; Hoshide, Satoshi ; Narita, Keisuke ; [et al.]

Ovid Technologies (Wolters Kluwer Health) ; 2021

In: Hypertension Vol. 78, No. 6 ( 2021-12), p. 1781-1790

add to watchlist on the watchlist

Details

In: Hypertension, Ovid Technologies (Wolters Kluwer Health), Vol. 78, No. 6 ( 2021-12), p. 1781-1790

Abstract: Resistant hypertension is an important cardiovascular risk factor. This analysis of the JAMP study (Japan Ambulatory Blood Pressure Monitoring Prospective) data investigated the effects of uncontrolled resistant hypertension diagnosed using ambulatory blood pressure (BP) monitoring on the risk of heart failure (HF) and overall cardiovascular events. The JAMP study patients with hypertension and no HF history were included. They had true resistant hypertension (24-hour BP ≥130/80 mm Hg), pseudoresistant hypertension (24-hour BP 〈 130/80 mm Hg), well-controlled nonresistant hypertension (24-hour BP 〈 130/80 mm Hg), or uncontrolled nonresistant hypertension (24-hour BP ≥130/80 mm Hg). The primary end point was total cardiovascular events, including atherosclerotic cardiovascular disease (fatal/nonfatal stroke and fatal/nonfatal coronary artery disease), and HF. During 4.5±2.4 years of follow-up the overall incidence per 1000 person-years was 10.1 for total cardiovascular disease, 4.1 for stroke, 3.5 for coronary artery disease, and 2.6 for HF. The adjusted risk of total cardiovascular and HF events was significantly increased in patients with true resistant versus controlled nonresistant hypertension (hazard ratio, 1.66 [95% CI, 1.12–2.48] ; P =0.012 and 2.24 [95% CI, 1.17–4.30]; P =0.015, respectively) and versus uncontrolled nonresistant hypertension (1.51 [1.03–2.20]; P =0.034 and 3.03 [1.58–5.83]; P 〈 0.001, respectively). The findings were robust in a sensitivity analysis using a slightly different definition of resistant hypertension. True resistant hypertension diagnosed using ambulatory BP monitoring is a significant independent risk factor for cardiovascular disease events, especially for HF. This highlights the importance of diagnosing and effectively treating resistant hypertension. Registration: URL: https://www.umin.ac.jp/ctr ; Unique identifier: UMIN000020377.

Type of Medium: Online Resource

ISSN: 0194-911X , 1524-4563

URL: Article

DOI: 10.1161/HYPERTENSIONAHA.121.18198

Language: English

Publisher: Ovid Technologies (Wolters Kluwer Health)

Publication Date: 2021

detail.hit.zdb_id: 2094210-2

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Pretransplant-corrected QT dispersion as a predictor of pericardial effusion after pediatric hematopoietic stem cell transplantation

Yanagisawa, Ryu ; Ishii, Eizaburo ; Motoki, Noriko ; [et al.]

Frontiers Media SA ; 2015

In: Transplant International Vol. 28, No. 5 ( 2015-05), p. 565-574

add to watchlist on the watchlist

Details

In: Transplant International, Frontiers Media SA, Vol. 28, No. 5 ( 2015-05), p. 565-574

Type of Medium: Online Resource

ISSN: 0934-0874

URL: Issue

URL: Article

DOI: 10.1111/tri.2015.28.issue-5

DOI: 10.1111/tri.12532

Language: English

Publisher: Frontiers Media SA

Publication Date: 2015

detail.hit.zdb_id: 1463183-0

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis

Chuma, Makoto ; Uojima, Haruki ; Hattori, Nobuhiro ; [et al.]

Wiley ; 2022

In: Hepatology Research Vol. 52, No. 3 ( 2022-03), p. 269-280

add to watchlist on the watchlist

Details

In: Hepatology Research, Wiley, Vol. 52, No. 3 ( 2022-03), p. 269-280

Abstract: To assess the impact of clinical factors on the safety and efficacy of atezolizumab plus bevacizumab (ATZ + BV) treatment in patients with unresectable hepatocellular carcinoma (u‐HCC). Method Ninety‐four u‐HCC patients who were treated with ATZ + BV at multiple centers were enrolled. We defined Child‐Pugh (CP)‐A patients who received ATZ + BV treatment as a first line therapy as the ‘meets the broad sense of the IMbrave150 criteria’ group (B‐IMbrave150‐in, n = 46), and patients who received ATZ + BV treatment as a later line therapy or CP‐B patients (regardless of whether ATZ + BV was a first line or later line therapy) as the B‐IMbrave150‐out group ( n = 48). Patients were retrospectively analyzed for adverse events (AEs) and treatment outcomes according to their clinical characteristics, including neutrophil lymphocyte ratio (NLR) at baseline. Results The overall incidence of AEs was 87.2% (82/94 patients). The frequency of interruption of ATZ + BV treatment due to fatigue was higher in CP‐B than CP‐A patients ( p = 0.030). Objective response (OR) rates of the B‐IMbrave150‐in group (28.3%, 39.1%) were significantly higher than those of the B‐IMbrave150‐out group (8.3%, 18.8%; p = 0.0157, 0.0401) using Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST, respectively. In multivariate analysis, NLR (hazard ratio (HR), 4.591; p = 0.0160) and B‐IMbrave150 criteria (HR, 4.108; p = 0.0261) were independent factors associated with the OR of ATZ + BV treatment using RECIST. Conclusion In real‐world practice, ATZ + BV treatment might offer significant benefits in patients who meet B‐IMbrave150 criteria or have low NLR.

Type of Medium: Online Resource

ISSN: 1386-6346 , 1872-034X

URL: Issue

URL: Article

DOI: 10.1111/hepr.v52.3

DOI: 10.1111/hepr.13732

Language: English

Publisher: Wiley

Publication Date: 2022

detail.hit.zdb_id: 2006439-1

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib

SASAKI, RYU ; FUKUSHIMA, MASANORI ; HARAGUCHI, MASAFUMI ; [et al.]

Anticancer Research USA Inc. ; 2021

In: Anticancer Research Vol. 41, No. 4 ( 2021-04), p. 2025-2032

add to watchlist on the watchlist

Details

In: Anticancer Research, Anticancer Research USA Inc., Vol. 41, No. 4 ( 2021-04), p. 2025-2032

Type of Medium: Online Resource

ISSN: 0250-7005 , 1791-7530

URL: Article

DOI: 10.21873/anticanres.14970

RVK:

XA 10000

Language: English

Publisher: Anticancer Research USA Inc.

Publication Date: 2021

detail.hit.zdb_id: 2145376-7

detail.hit.zdb_id: 604549-2

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Immunological Study on Serum of Patients with Periodontal disease

TANI, Akira ; MORI, Shoichi ; HIDAKA, Satoshi ; [et al.]

Japanese Society of Periodontology ; 1977

In: Nihon Shishubyo Gakkai Kaishi (Journal of the Japanese Society of Periodontology) Vol. 19, No. 1 ( 1977), p. 47-52

add to watchlist on the watchlist

Details

In: Nihon Shishubyo Gakkai Kaishi (Journal of the Japanese Society of Periodontology), Japanese Society of Periodontology, Vol. 19, No. 1 ( 1977), p. 47-52

Type of Medium: Online Resource

ISSN: 0385-0110 , 1880-408X

Uniform Title: 歯周疾患患者血清の免疫学的研究

URL: Article

DOI: 10.2329/perio.19.47

Language: Japanese , Japanese

Publisher: Japanese Society of Periodontology

Publication Date: 1977

detail.hit.zdb_id: 2218241-X

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma

Kobayashi, Satoshi ; Fukushima, Taito ; Ueno, Makoto ; [et al.]

Springer Science and Business Media LLC ; 2022

In: BMC Cancer Vol. 22, No. 1 ( 2022-12)

add to watchlist on the watchlist

Details

In: BMC Cancer, Springer Science and Business Media LLC, Vol. 22, No. 1 ( 2022-12)

Abstract: Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer [BCLC] B). However, it often leads to a poor prognosis and decreased hepatic function especially in patients with BCLC substage B2. Lenvatinib (LEN) was demonstrated to be efficacious in these patients in the REFLECT phase 3 trial. We therefore aimed to evaluate the efficacy and safety of LEN as a first-line treatment for the patients with HCC at BCLC substage B2. Methods This prospective observational study used LEN in TACE-naïve patients with HCC at BCLC substage B2 and preserved hepatic function. The primary endpoint was overall survival. A one-year survival rate threshold of 60% and an expected survival rate of 78%, based on previous reports of TACE, was assumed for setting the sample size. With a one-sided α-type error of 5% and 70% detection power, 25 patients were required over a 2-year enrollment period and 10-month follow-up period. Results Thirty-one patients were enrolled in this study from June 2018 to June 2020. The 1-year survival rate was 71.0% (90% confidence interval, 68.4–73.6%). Median overall and progression-free survival periods were 17.0 and 10.4 months, and the objective response rates according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 and modified RECIST criteria were 22.6% and 70.0%, respectively. Common adverse events (AEs) were fatigue (68%), hypertension (65%), anorexia (61%), palmar-plantar erythrodysesthesia (39%), and thrombocytopenia (32%) of any grade; aspartate aminotransferase increased (23%), alanine aminotransferase increased (16%), and grade ≥ 3 proteinuria (13%). Treatment interruption and dose reduction were required in 61% and 81% of patients, respectively. LEN was discontinued in 29 patients due to disease progression ( n = 17), AEs ( n = 9), conversion to curative treatments ( n = 2), and sudden death ( n = 1), whereas post-LEN treatments were administered in 18 patients, including systemic chemotherapy ( n = 11), TACE ( n = 6), transarterial infusion ( n = 1) and clinical trial ( n = 1). Conclusions The results suggest that LEN provides treatment benefits as an initial therapeutic in patients with BCLC substage B2 HCC with a safety profile comparable to that previously reported.

Type of Medium: Online Resource

ISSN: 1471-2407

URL: Article

DOI: 10.1186/s12885-022-09625-x

Language: English

Publisher: Springer Science and Business Media LLC

Publication Date: 2022

detail.hit.zdb_id: 2041352-X

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Prenatal diagnosis of trisomy 16 mosaicism manifested as pulmonary artery stenosis

Hidaka, Nobuhiro ; Yamamoto, Nari ; Tsukimori, Kiyomi ; [et al.]

Wiley ; 2009

In: Journal of Clinical Ultrasound Vol. 37, No. 2 ( 2009-02), p. 107-111

add to watchlist on the watchlist

Details

In: Journal of Clinical Ultrasound, Wiley, Vol. 37, No. 2 ( 2009-02), p. 107-111

Type of Medium: Online Resource

ISSN: 0091-2751 , 1097-0096

URL: Issue

URL: Article

DOI: 10.1002/jcu.v37:2

DOI: 10.1002/jcu.20499

Language: English

Publisher: Wiley

Publication Date: 2009

detail.hit.zdb_id: 1492376-2

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

Online Resource

Protein C activity as a potential prognostic factor for nursing home-acquired pneumonia

Oi, Issei ; Ito, Isao ; Tanabe, Naoya ; [et al.]

Public Library of Science (PLoS) ; 2022

In: PLOS ONE Vol. 17, No. 10 ( 2022-10-12), p. e0274685-

add to watchlist on the watchlist

Details

In: PLOS ONE, Public Library of Science (PLoS), Vol. 17, No. 10 ( 2022-10-12), p. e0274685-

Abstract: Despite the poor prognosis for nursing home acquired pneumonia (NHAP), a useful prognostic factor is lacking. We evaluated protein C (PC) activity as a predictor of in-hospital death in patients with NHAP and community-acquired pneumonia (CAP). Methods This prospective, observational study included all patients hospitalized with pneumonia between July 2007 and December 2012 in a single hospital. We measured PC activity at admission and investigated whether it was different between survivors and non-survivors. We also examined whether PC activity 〈 55% was a predictor for in-hospital death of pneumonia by logistic regression analysis with CURB-65 items (confusion, blood urea 〉 20 mg/dL, respiratory rate 〉 30/min, and blood pressure 〈 90/60 mmHg, age 〉 65). When it was a useful prognostic factor for pneumonia, we combined PC activity with the existing prognostic scores, the pneumonia severity index (PSI) and CURB-65, and analyzed its additional effect by comparing the areas under the receiver operating characteristic curves (AUCs) of the modified and original scores. Results Participants comprised 75 NHAP and 315 CAP patients. PC activity was lower among non-survivors than among survivors in NHAP and all-pneumonia (CAP+NHAP). PC activity 〈 55% was a useful prognostic predictor for NHAP (Odds ratio 7.39 (95% CI; 1.59–34.38), and when PSI or CURB-65 was combined with PC activity, the AUC improved (from 0.712 to 0.820 for PSI, and 0.657 to 0.734 for CURB-65). Conclusions PC activity was useful for predicting in-hospital death of pneumonia, especially in NHAP, and became more useful when combined with the PSI or CURB-65.

Type of Medium: Online Resource

ISSN: 1932-6203

URL: Article

DOI: 10.1371/journal.pone.0274685

DOI: 10.1371/journal.pone.0274685.g001

DOI: 10.1371/journal.pone.0274685.g002

DOI: 10.1371/journal.pone.0274685.g003

DOI: 10.1371/journal.pone.0274685.g004

DOI: 10.1371/journal.pone.0274685.g005

DOI: 10.1371/journal.pone.0274685.t001

DOI: 10.1371/journal.pone.0274685.t002

DOI: 10.1371/journal.pone.0274685.t003

DOI: 10.1371/journal.pone.0274685.t004

DOI: 10.1371/journal.pone.0274685.t005

DOI: 10.1371/journal.pone.0274685.s001

DOI: 10.1371/journal.pone.0274685.s002

Language: English

Publisher: Public Library of Science (PLoS)

Publication Date: 2022

detail.hit.zdb_id: 2267670-3

Bookmarklink

Library	Location	Call Number	Volume/Issue/Year	Availability

Others were also interested in ...

Online Resource

Open Access Request

Availability (electronic / print)

Link to publisher

hits 1 - 10 | 534 hits

Nothing or not found what you are looking for? Please check your search query or use the Interlibrary Loan Search.

Kooperativer Bibliotheksverbund

Berlin Brandenburg